Immune checkpoint inhibition in the treatment of early stage triple negative breast cancer: 2021 update

There is an emerging body of evidence regarding the use of immunotherapy in early-stage triple negative breast cancer (TNBC), with the recent publication of several phase III and randomised phase II studies examining the role of immune checkpoint inhibitors (ICI) in the neoadjuvant setting in combin...

Full description

Bibliographic Details
Main Authors: Lauren C. Brown, Sherene Loi
Format: Article
Language:English
Published: Elsevier 2022-03-01
Series:Breast
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S0960977621010250